Pharming Group NV (PHAR) News
Filter PHAR News Items
PHAR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PHAR News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest PHAR News From Around the Web
Below are the latest news stories about PHARMING GROUP NV that investors may wish to consider to help them evaluate PHAR as an investment opportunity.
3 Promising Penny Stocks With At Least US$80M Market CapAmid recent global market fluctuations, with U.S. stocks experiencing a decline due to cautious Federal Reserve commentary and political uncertainties, investors are increasingly looking for opportunities in less conventional areas of the market. Penny stocks, often representing smaller or newer companies, can still offer significant potential for growth despite their historical connotations. By focusing on those with strong financials and clear growth prospects, investors may find compelling... |
Pharming announces public cash offer to the shareholders of Abliva ABProposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases Total transaction value of approximately US$66.1 million No external funding required to fund acquisition and KL1333 development costs Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (8:00 am ES |
European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder DrugOn Wednesday, Pharming Group N.V. (NASDAQ:PHAR) revealed topline results of data from its Phase 3 trial evaluating leniolisib in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a genetic disorder that impairs the immune system. Individuals with this condition often have low numbers of white blood cells, particularly certain types of B and T cells. These cells are necessary to recognize and attack foreign invaders, such as viruses and bacteria, |
Pharming announces positive topline data in pediatric clinical trial of leniolisibMultinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Data consistent with the improvements seen in the previously reported randomized controlled trial in adolescent and adult APDS patients Global regulatory filings planned to begin in 2025 Leiden, the Netherlands, December 11, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces positive topline results of dat |
High Growth Tech Stocks To Watch For Potential GrowthIn recent weeks, global markets have experienced notable gains, with small-cap indices like the Russell 2000 reaching record highs amid a backdrop of geopolitical developments and domestic policy shifts. As investors navigate these dynamic conditions, identifying high-growth tech stocks requires a keen eye on innovation potential and market adaptability to capitalize on evolving economic landscapes. |
Pharming Group And 2 Other Promising Penny Stocks To WatchAs global markets show resilience with U.S. indexes approaching record highs, investors are keeping a close eye on economic indicators such as jobless claims and home sales reports that drive positive sentiment. For those willing to explore beyond the well-known names, penny stocks—often representing smaller or newer companies—remain a relevant investment area despite being considered somewhat outdated. These stocks can offer unique growth opportunities at lower price points, especially when... |
Pharming Group to participate in November investor conferenceLeiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of November: Jefferies London Healthcare Conference 2024, London, U.K., November 19-21Sijmen de Vries, Chief Executive Officer, will present on Wednesday, November 20 at 08:00 GMT/09:00 CET. A live webcast and replay of the presentation will be available in the “Upcoming Events” |
High Growth Tech And 2 Other Promising Stocks To WatchAs global markets navigate a turbulent landscape marked by lower stock performances amid busy earnings reports and mixed economic signals, small-cap stocks have demonstrated resilience compared to their larger counterparts. In this environment, identifying promising investment opportunities requires a keen eye for companies with strong fundamentals and the potential to thrive in sectors like high-growth tech, where innovation can drive significant returns. |
Pharming Group (PHGUF) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...Pharming Group (PHGUF) reports a 12% revenue increase in Q3 2024, driven by Ruconest and Joenja, while navigating operational losses and market expansion efforts. |
Pharming Group reports third quarter 2024 financial results and provides business updateThird quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja® revenue growthRUCONEST® third quarter revenue increased by 6% to US$63.6 million, compared to the third quarter 2023Joenja® (leniolisib) third quarter revenue increased by 72% to US$11.2 million, compared to the third quarter 2023 First nine months total revenues increased by 25% to US$204.5 million, compared to the first nine months 2023On t |